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Advax is a polysaccharide-based adjuvant that potently stimulates vaccine immunogenicity
without the increased reactogenicity seen with other adjuvants. This study investigated the
immunogenicity of a novel Advax-adjuvanted Vero cell culture candidate vaccine against Japanese
encephalitis virus (JEV) in mice and horses. The results showed that, in mice, a two-immunization,
low-dose (50 ng JEV antigen) regimen with adjuvanted vaccine produced solid neutralizing
immunity comparable to that elicited with live ChimeriVax-JE immunization and superior to that
elicited with tenfold higher doses of a traditional non-adjuvanted JEV vaccine (JE-VAX; Biken
Institute) or a newly approved alum-adjuvanted vaccine (Jespect; Novartis). Mice vaccinated with
the Advax-adjuvanted, but not the unadjuvanted vaccine, were protected against live JEV
challenge. Equine immunizations against JEV with Advax-formulated vaccine similarly showed
enhanced vaccine immunogenicity, confirming that the adjuvant effects of Advax are not restricted
to rodent models. Advax-adjuvanted JEV vaccine elicited a balanced T-helper 1 (Th1)/Th2
immune response against JEV with protective levels of cross-neutralizing antibody against other
viruses belonging to the JEV serocomplex, including Murray Valley encephalitis virus (MVEV). The
adjuvanted JEV vaccine was well tolerated with minimal reactogenicity and no systemic toxicity in
immunized animals. The cessation of manufacture of traditional mouse brain-derived unadjuvanted
JEV vaccine in Japan has resulted in a JEV vaccine shortage internationally. There is also an
ongoing lack of human vaccines against other JEV serocomplex flaviviruses, such as MVEV,
making this adjuvanted, cell culture-grown JEV vaccine a promising candidate to address both
needs with one vaccine.
INTRODUCTION
Japanese encephalitis (JE) is an acute central nervous
system inflammatory disease caused by infection with the
flavivirus Japanese encephalitis virus (JEV; reviewed by
Solomon, 2004). It is the leading cause of viral encephalitis
in South-East Asia, India and China. The geographical
distribution of JEV is expanding, most recently in south-
west India, the eastern Indonesian archipelago, New
Guinea and the Torres Strait of Northern Australia
(reviewed by Mackenzie et al., 2004). Annually, ~35000
human cases of JE are reported, resulting in about 10000
deaths and a high incidence of neuropsychiatric deficits
among survivors. Children as well as non-immune adults
are predominantly at risk of contracting the disease in
endemic areas. JEV is an arbovirus and is transmitted by
Culex mosquitoes to its vertebrate hosts (wild and
domestic birds, and pigs); human infections with JEV do
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the transmission cycle. JE is also a veterinary disease with
occasional fatal outcome in horses, and abortions and
abnormal births in pigs.
Vaccination is the most effective means of preventing JEV
infection and should be practised routinely in regions where
the virus is responsible for human and veterinary disease
(reviewed by Halstead & Tsai, 2004; Monath, 2002a). In the
1960s, an inactivated JE vaccine (JE-VAX; Biken Institute)
produced from infected mouse brain was developed in Japan
and licensed for use internationally. A three-dose vaccination
regimen with this vaccine resulted in time-limited immunity
in about 90% of immunized individuals (Hoke et al., 1988;
Monath, 2002a). Whilst intermittent natural exposure to JEV
in endemic areas probably gives rise to boosting of waning
vaccine-induced immunity (Konishi & Suzuki, 2002), vaccine
protection of individuals living in non-endemic regions
requires regular vaccine boosters. In 2005, the Japanese
government ceased its recommendation of the routine use of
the mouse brain-grown JE vaccine, due to perceived safety
problems and excess reactogenicity (Fischer et al., 2007). The
motivation for this change in policy was anticipation that
JE-VAX would be replaced by cell culture-grown inactivated
JE (ccJE) vaccines under development by manufacturers in
Japan, the USA, Europe and India. Several Vero cell-grown
vaccines have undergone phase 2 and phase 3 trials to
compare their safety and efficacy in humans with licensed
mouse brain-grown vaccine (reviewed by Beasley etal., 2008).
Non-inferiority to JE-VAX has been the primary end point
forefficacytesting ofnewJEvaccinecandidates(Beasley et al.,
2008; Ferguson et al., 2007). Other JE vaccines that are in use
or undergoing clinical trials are a live, attenuated vaccine
(SA14-14-2 strain) used in China (reviewed by Halstead &
Tsai, 2004; Monath, 2002a) and an as yet unapproved
live, recombinant vaccine (ChimeriVax-JE) engineered by
replacement of the immunogenic virion surface proteins, prM
and E, in a yellow fever virus vaccine with those of JEV
(Monath et al.,2 0 0 3 ) .U s eo fS A 1 4 - 1 4 - 2l i v eJ Ev a c c i n ei n
countries outside China is restricted by the uncertainty of
quality control for adventitious agents in the uncharacterized
cell line used for vaccine production.
The geographical expansion of JEV has resulted in endemic
transmission of the virus in regions where antigenically
closely related and medically important flaviviruses co-exist,
i.e. West Nile virus (WNV) in India, and Murray Valley
encephalitis virus (MVEV) and WNV in the Australasian
region. In animal models, live infection with one of these
viruses produces long-lived, cross-protective immunity
against the others (Goverdhan et al., 1992; Hammon &
Sather,1956;Monath,2002b;Tsaietal.,1998;Williamsetal.,
2001). However, in laboratory investigations, vaccination
against JEV and related encephalitic flaviviruses has been
associated with either cross-protective immunity (Chu et al.,
2007; Lobigs et al., 2003, 2009; Martina et al., 2008; Takasaki
et al., 2003) or disease-enhancing immunity (Broom et al.,
2000; Lobigs et al., 2003, 2009; Wallace et al., 2003) against
other viruses belonging to the JEV serocomplex. The latter is
thought to be a consequence of the antibody-dependent
enhancement phenomenon first described in studies with
MVEV and WNV in vitro (Hawkes, 1964), and subsequently
postulated to be the basis for the more severe disease
associated with secondary dengue virus infections (reviewed
by Halstead, 2003). The laboratory finding of instances of
vaccine-induced enhancement of heterologous flavivirus
infection is of some concern in relation to JE vaccine safety
in humans, especially in regions where closely related
flaviviruses are endemic. Vaccine efficacy in terms of
magnitude and/or quality of the humoral immune response
may be key to preventing infection enhancement (Lobigs
et al., 2003, 2009).
The immunogenicity of inactivated vaccines can be signifi-
cantly augmented by formulation with an appropriate
adjuvant. A Vero cell-grown JE vaccine, IC51 (Jespect;
Novartis) (Tauber et al., 2007), recently licensed in the USA
and Australia, and other candidate ccJE vaccines
(Appaiahgari & Vrati, 2004; Srivastava et al., 2001; Tauber
et al., 2007) are formulated with aluminium hydroxide
(alum), whilst other candidate vaccines have been left
unadjuvanted (Kuzuhara et al., 2003; Sugawara et al., 2002;
Toriniwa & Komiya,2008).Alum adjuvants, whilstapproved
for human use, suffer from a number of disadvantages: the
benefits of modest enhancement of antibody titres are often
offset by increased injection-site pain and the potential for
long-term granuloma formation and induction of eosino-
philia (reviewed by Gupta, 1998). The ideal adjuvant for JE
vaccines should enhance neutralizing antibody titres, have
significant antigen-sparing potential and be well-tolerated
and safe. Immunologically active polysaccharide particles
such as delta inulin, on which the Advax family of adjuvants
is based, have emerged as strong candidates for use ashuman
vaccine adjuvants, combining potent adjuvant efficacy with
good tolerability and safety (Petrovsky, 2006, 2008; Silva
et al., 2004). Delta inulin adjuvants have been found to
enhance neutralizing antibody and cellular immune
responses and to provide antigen sparing when combined
with a range of vaccine antigens including inactivated
RNA viruses, e.g. seasonal or pandemic influenza vaccine
(unpublished results). The purpose of this study was to
examine the ability of Advax adjuvant to enhance the
potency and provide dose sparing for a new ccJE vaccine
under development in Japan (Toriniwa & Komiya, 2008).
Given that natural infection with JEV is known to protect
against related flaviviruses, our second objective was to assess
the potential for an Advax-adjuvanted ccJE vaccine to
provide JEV serocomplex cross-protective immunity.
RESULTS
A delta inulin-based adjuvant potentiates virus-
specific humoral immunity elicited with a Vero
cell-grown inactivated JE vaccine
Formalin-inactivated JEV derived from Vero cells cultured
in serum-free medium (ccJE) was obtained from the
M. Lobigs and others
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investigate whether the efficacy of this unadjuvanted ccJE
formulation could be enhanced by inclusion of Advax, a
delta inulin-based adjuvant, JEV-specific antibody
responses elicited in mice by adjuvanted and non-
adjuvanted ccJE given as a two-dose vaccination schedule
were compared. For an additional immunogenicity com-
parison, a group of mice was also immunized with a
comparable dose (0.5 mg) of JE-VAX, which corresponds
to approximately one-tenth of the dose recommended for
human use. Formulation of ccJE with Advax adjuvant
potentiated the antibody response induced against JEV,
measured by ELISA, by approximately 100-fold relative to
the non-adjuvanted control groups in two independent
experiments (P,0.001; Table 1). Unadjuvanted ccJE was
marginally more immunogenic than JE-VAX (P50.03,
when data from experiments 1 and 2 in Table 1 were
combined), as has been reported previously (Toriniwa &
Komiya, 2008).
Virus-neutralizing antibody is key to protection against JE
(reviewed by Mullbacher et al., 2003): a titre of ¢10 in a
50% plaque-reduction neutralization test (PRNT50)i s
indicative of protective immunity (Hombach et al., 2005).
Formulation of ccJE with Advax resulted in potently
increased neutralizing antibody responses against JEV in
comparison with control groups (Table 1). Importantly,
each recipient of the Advax-adjuvanted vaccine generated
PRNT50 titres ¢40 in two independent experiments. This
contrasted markedly with the marginal PRNT50 responses
elicited by the unadjuvanted vaccines, which failed to
induce detectable neutralizing antibody in 31 and 56% of
recipients of JE-VAX and ccJE, respectively (combined
results from experiments 1 and 2 in Table 1).
Immunization with JE-VAX gave marginally higher
PRNT50 responses against JEV than ccJE, despite higher
ELISA end-point titres obtained for ccJE than JE-VAX
(Table 1). The probable explanation for this discrepancy is
the effect of JEV strain differences on neutralization
(Ferguson et al., 2008), as the JE-VAX and ccJE vaccines
are produced from the Nakayama and Beijing-1 strains,
respectively, and neutralization against the Nakayama
strain was measured.
Adjuvanted ccJE protects mice against challenge
with JEV
Groups of mice vaccinated with two doses of ccJE (0.5 mg)
in the presence or absence of Advax adjuvant, or with
comparable doses of JE-VAX, were challenged intranasally
with the Nakayama strain of JEV at 6 weeks after
completion of the vaccination schedule (Fig. 1). This
challenge route is thought to result in entry of the virus
into the olfactory lobe of the brain via the olfactory nerve
and is less severe than direct intracranial infection (Barrett
& Gould, 1986). Whilst 47% of naı ¨ve mice succumbed to
the virus challenge, all animals immunized with the Advax-
adjuvanted vaccine survived (P50.026) without showing
the characteristic signs of flaviviral encephalitis (ruffled fur,
hunched posture, tremors and hind-leg paralysis).
Interestingly, recipient groups of non-adjuvanted ccJE or
JE-VAX showed an indication, although not significant
(P50.23 and P50.67, respectively), towards increased
mortality and reduced mean survival time relative to
the untreated mice, which may reflect disease-enhancing
immunity.
Formulation of ccJE with Advax stimulates
balanced T-helper cell 1 (Th1)/Th2 antibody
responses
Live virus infection typically elicits a Th1-biased immune
response characterized by the secretion of gamma
interferon, efficient cellular immune responses and the
Table 1. Antibody responses against JEV and related flaviviruses
Vaccine* Mean log10 antibody titreD Mean PRNT50 titred
JEV MVEV WNV
Experiment 1
JE-VAX 2.7 (,2.0–3.5) 13 (,10–40) ,10 ,10
ccJE 3.4 (,2.0–4.4) 7.5 (,10–10) ,10 ,10
ccJE+Advax 5.4 (5.1–5.7) 380 (40–2000) 40 10
Experiment 2
JE-VAX 3.0 (2.3–3.8) 21 (,10–40) ,10 ,10
ccJE 3.4 (2.3–4.1) 10 (,10–40) ,10 ,10
ccJE+Advax 5.3 (4.5–6.0) 250 (40–1000) 160 20
*Groups of 8-week-old C57Bl/6 mice (n58 per group) were immunized with 0.5 mg JE-VAX or ccJE without or mixed with Advax adjuvant and
boosted 3 weeks later. Sera were collected at 6 weeks after completion of the vaccination schedule.
DELISA end-point titres of individual test sera were determined as described in Methods; mean titres and the range are given.
dPlaque reduction neutralization by individual test sera against JEV (strain Nakayama) and pooled sera against MVEV (strain MVE-1-51) and
WNV (strain Kunjin MRM61C) were determined as described in Methods; mean titres and the ranges are given.
Cross-protective JE vaccine
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IgG2a/2b isotypes (Coutelier et al., 1987). IgG2a/2b
isotypes have been associated with more efficient virus
clearance in vivo in comparison with the IgG1 isotype,
reflective of a Th2 immune response (see, for example,
Huber et al., 2006; Markine-Goriaynoff & Coutelier, 2002;
Nimmerjahn & Ravetch, 2005). The choice of vaccine
adjuvant can bias the nature of the immune response and
hence the antibody isotypes elicited; this is exemplified by
alum, which promotes Th2 bias and elevated titres of IgG1
and IgE in vivo (reviewed by McKee et al., 2007). In
contrast, inulin-based adjuvants provide balanced
enhancement of both cellular (Th1) and humoral (Th2)
immunity (Petrovsky, 2006). The results shown in Table 2
confirmed that formulation of ccJE with Advax elicited a
balanced response in terms of the Th1/Th2 paradigm. High
levels of JEV-specific IgG1 and IgG2b isotype antibodies
were obtained in two independent experiments, with an
IgG2b:IgG1 isotype ratio in the range of 1.1–2.1. This was
comparable to the ratios found in recipients of unadju-
vanted vaccines, although the titres for these were
significantly lower, consistent with the lower ELISA end-
point titres relative to those elicited with the adjuvanted
vaccine (Table 1). As C57Bl/6 mice lack the gene for IgG2a
(Martin et al., 1998), stimulation of this subclass of Th1
type antibody could not be investigated in this mouse
strain.
Dose-sparing effect of Advax adjuvant in
formulation with ccJE
Our results showed that the magnitude of the humoral
immune response induced with inactivated JE vaccine was
significantly increased by mixing with the delta inulin
adjuvant. To test whether inclusion of Advax adjuvant with
ccJE would permit antigen sparing, the antigen dose was
lowered to 50 ng in a two-dose vaccination regimen and
JEV-specific antibody responses were measured. A signifi-
cantly higherELISA end-point (P50.008) and PRNT50titres
(P50.03) against JEV were achieved with the low antigen
dose with Advax adjuvant compared with a tenfold higher
antigen dose without adjuvant (Table 3). Remarkably,
Advax-adjuvanted low-antigen-dose vaccinations elicited
PRNT50 titres ¢10 against JEV in all mice, whereas six
Fig. 1. Protection against JEV challenge with adjuvanted ccJE
vaccine. Groups of 8-week-old C57Bl/6 mice were immunized
with 0.5 mg JE-VAX or ccJE without or formulated with Advax
adjuvant and boosted 3 weeks later. For pre-challenge serology,
see Table 1, experiment 1. At 6 weeks after completion of the
vaccination schedule, mice were challenged intranasally with
210
5 p.f.u. JEV (Nakayama strain). Mice were monitored twice
daily for morbidity and mortality for 28 days.
Table 2. JEV-specific antibody isotypes elicited by immunization with inactivated JEV vaccines
formulated with or without Advax adjuvant
Vaccine* Anti-JEV antibody isotype titreD Isotype ratio (IgG2b/IgG1)
IgG1 IgG2b
Experiment 1
JE-VAX 1.5 (0.2) 0.9 (0.3) 0.6
ccJE 2.9 (1.1) 7.5 (3.1) 2.5
ccJE+Advax 7.3 (0.7) 15.2 (1.6) 2.1
Experiment 2
JE-VAX 1.4 (0.4) 2.6 (1.5) 1.9
ccJE 3.3 (0.6) 4.2 (1.2) 1.3
ccJE+Advax 9.2 (1.7) 10.3 (2.5) 1.1
*Groups of 8-week-old C57Bl/6 mice (n58 per group) were immunized with 0.5 mg JE-VAX or ccJE without or
mixed with Advax adjuvant and boosted 3 weeks later. Sera were collected at 6 weeks after completion of the
vaccination schedule. For JEV-specific ELISA antibody titres, see Table 1.
DThe relative antibody isotypes of pooled test sera were calculated as described in Methods; the mean of two
determinations (SEM in parentheses) is given.
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groups immunized with 50 ng or even 0.5 mgc c J E ,
respectively, failed to produce detectable neutralizing anti-
body. For comparison, the live, recombinant ChimeriVax-JE
vaccine was also included in the dose-sparing study. Prime
and booster vaccinations with 10
5 p.f.u. ChimeriVax-JE
elicited a level of humoral immunity against JEV comparable
to that achieved with the Advax-adjuvanted 50 ng low-
antigen-dose immunization, but was clearly inferior to that
induced with the adjuvanted 0.5 mgc c J Ed o s e( T a b l e3 ) .
Heterologous prime–boost with Advax-
adjuvanted ccJE and ChimeriVax-JE
Heterologous prime–boost vaccination with live followed by
inactivated vaccines can result in remarkable augmentation
of immune responses in comparison with homologous
prime–boost with either of the vaccines alone (reviewed
by Ranasinghe & Ramshaw, 2009). To investigate whether
the humoral immune responses induced with Advax-
adjuvanted ccJE could be further enhanced by heterologous
prime–boost with ChimeriVax-JE, different homologous
and heterologous prime–boost combinations with the two
vaccines were tested (Table 4). As shown above (Table 3), a
two-dose vaccination schedule with Advax-adjuvanted ccJE
provided significantly higher JEV-specific ELISA (P50.01)
and PRNT50 (P50.05) antibody titres than ChimeriVax-JE.
Notably, neither combination of heterologous prime–boost
with the two vaccines augmented the JEV-specific antibody
responses relative to mice immunized with two doses of
Advax-adjuvanted ccJE, although improved responses were
obtainedincomparisonwithhomologousprime–boostwith
ChimeriVax-JE.
Comparison of the immune-potentiating value of
Advax and alum adjuvants in formulation with JE
vaccines
The recently licensed Vero cell-grown JE vaccine IC51
(Jespect) is adjuvanted with alum (Tauber et al., 2007).
Hence, it was of interest to compare the immune-
enhancing effect of Advax and alum when used to adjuvant
ccJE vaccines. Experiments conducted in BALB/c mice
again confirmed the potent adjuvant effect of Advax in
augmenting JEV-specific antibody responses elicited with
the ccJE vaccine relative to unadjuvanted vaccine delivery
when measured by ELISA (P50.004) and neutralization
assay (P50.01; Table 5, experiment 1). Notably, all animals
in the ccJE+Advax group showed PRNT50 titres ¢20
against JEV, whilst three out of five mice in the
unadjuvanted ccJE group failed to produce detectable
titres. Alum was poorer at immune potentiating the ccJE
vaccine relative to Advax with a significant difference
found in the PRNT50 titres against JEV (P50.01).
Table 3. Dose-sparing potency of Advax adjuvant in formulation with ccJE vaccine
Vaccine* Dose No. of mice per group Mean log10 antibody titre Mean PRNT50 titre
ccJE 0.5 mg 6 3.5 (2.9–4.4) 12 (,10–20)
0.05 mg 7 2.4 (,2.0–3.2) 6 (,10–10)
ccJE+Advax 0.5 mg6¢5.5 (5.1–.5.7) 160 (pool only)
0.05 mg 7 4.6 (3.9–5.4) 49 (10–80)
ChimeriVax-JE 10
5 p.f.u. 6 4.6 (3.6–5.4) 40 (pool only)
*Groups of 8-week-old C57Bl/6 mice were immunized subcutaneously with tenfold-different amounts of ccJE without or mixed with Advax
adjuvant, or with ChimeriVax-JE vaccine, and boosted 3 weeks later with the same doses that were used for priming. At 6 weeks after completion of
the vaccination schedule, sera were collected and mean JEV-specific ELISA end-point and PRNT50 titres (ranges in parentheses) were determined.
Table 4. Homologous and heterologous prime–boost with Advax-adjuvanted ccJE and ChimeriVax-JE
vaccines
Vaccine* Mean log10 antibody titre Mean PRNT50 titre
Prime Boost
ccJE+Advax ccJE+Advax 4.9 (4.5–5.4) 76 (20–160)
ChimeriVax-JE ChimeriVax-JE 3.4 (2.7–3.9) 21 (,10–80)
ChimeriVax-JE ccJE+Advax 4.8 (4.5–5.4) 60 (20–80)
ccJE+Advax ChimeriVax-JE 4.5 (4.2–4.8) 40 (10–80)
*Advax-adjuvanted ccJE (0.5 mg) and Chimerivax-JE (10
5 p.f.u.) were used for immunizations. Groups of 8-
week-old C57Bl/6 mice (n55 per group) were primed and boosted 2 weeks later as indicated. Sera were
collected 3 weeks after completion of the vaccination schedules and mean JEV-specific ELISA end-point and
PRNT50 titres (ranges in parentheses) of individual sera were determined.
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adjuvanted ccJE with that of the Jespect JE vaccine
(Tauber et al., 2007) in a dose-sparing experiment (Table
5, experiment 2). Whilst comparable levels of virus-specific
antibody responses were elicited with 0.5 mg antigen, a
tenfold reduction in antigen dose revealed that Advax-
adjuvanted ccJE was significantly more potent than Jespect
in inducing protective humoral immunity against JEV
(P,0.001 and P,0.03 in ELISA and PRNT50, respectively).
Advax adjuvant stimulates protective neutralizing
antibody responses against heterologous viruses
belonging to the JEV serocomplex
Neutralizing antibody against MVEV and WNV elicited
with Advax-adjuvanted ccJE in C57Bl/6 mice was measured
in two independent experiments (Table 1). MVEV-specific
PRNT50 titres of pooled sera ranging from 40 to 160 were
observed; these titres suggested that solid cross-protective
immunity against MVEV was achieved with the adjuvanted
ccJE vaccine. Consistent with the greater genetic distance
between WNV and JEV compared with MVEV and JEV,
the WNV-specific PRNT50 titres were lower (10–20) but
nevertheless predictive of cross-protection. Notably, the
neutralization titres against the heterologous viruses
achieved with Advax-adjuvanted ccJE were equal to or
greater than those against the homologous virus obtained
with unadjuvanted ccJE or JE-VAX; the latter vaccinations
gave no detectable cross-neutralizing activity against either
MVEV or WNV. Similar results were obtained in BALB/c
mice (Table 5). Importantly, all animals responded with
PRNT50 titres ¢10 against MVEV when immunized with
Advax-adjuvanted ccJE. However, a comparable level of
cross-protective immunity against MVEV was not achieved
in Jespect-immunized mice (Table 5).
To expand on these findings, the cross-neutralization
activity against MVEV of immune responses elicited with
Advax-adjuvanted or unadjuvanted JE-VAX was compared
with that induced with ChimeriVax-JE (Fig. 2). Vaccination
with Advax-adjuvanted JE-VAX induced marginally greater
anti-JEV ELISA titres than ChimeriVax-JE (P50.06) and
were .50-fold higher in magnitude than those achieved
with unadjuvanted JE-VAX. However, the anti-MVEV
PRNT50 titres in Advax-adjuvanted JE-VAX immunized
mice were significantly higher than in ChimeriVax-JE
vaccine recipients (P50.03) and yet again exceeded the
threshold considered to be required for protective immunity
(PRNT50 ¢10) in all animals. Unadjuvanted JE-VAX
failed to elicit detectable neutralizing antibodies against
MVEV. JEV-specific PRNT50 titres of pooled sera from
the unadjuvanted and Advax-adjuvanted JE-VAX and
ChimeriVax-JE vaccine recipients were 20, 200 and 80,
respectively, consistent with the observation throughout this
study that the magnitude of the neutralizing antibody
response against the homologous virus correlates with that
against other flaviviruses belonging to the JEV serocomplex.
Efficacy of Advax-adjuvanted ccJE vaccine in
horses
Horses are susceptible to infection with JEV and are
vaccinated in endemic regions against the virus to protect
them from a potentially fatal encephalitis. Accordingly,
they are a suitable large-animal model for pre-clinical JE
vaccine trials. Horses were immunized with a standard
human dose of JE-VAX (6 mg JEV antigen) or an
Table 5. Comparison of the immunogenicity of Advax- and alum-adjuvanted cell culture-grown JE
vaccines in BALB/c mice
NT, Not tested.
Vaccine* Dose (mg) Mean log10 antibody titre Mean PRNT50 titre
JEV MVEV
Experiment 1
ccJE 0.5 4.0 (3.6–4.2) 13 (,10–40) ,10 (pool only)
ccJE+Advax 0.5 4.9 (4.5–¢5.4) 77 (20–160) 20 (pool only)
ccJE+alum 0.5 4.3 (3.6–5.1) 16 (,10–20) 10 (pool only)
Experiment 2
ccJE+Advax 0.5 ¢4.8 (3.9–¢5.1) 124 (20–320) 18 (10–30)
0.05 4.6 (4.2–4.8) 74 (10–160) NT
Jespect 0.5 3.6 (3.2–4.1) 100 (20–320) 8 (,10–10)
0.05 2.7 (,2.3–4.1) 6 (,10–10) NT
*In experiment 1, groups of 8-week-old BALB/c mice (n56 per group) were immunized subcutaneously with
ccJE without or mixed with Advax or alum adjuvant and boosted 3 weeks later. In experiment 2, groups of mice
(n510 per group) were immunized with tenfold different amounts of Advax-adjuvanted ccJE or with (Jespect
and boosted 3 weeks later. At 4 weeks after completion of the vaccination schedules, sera were collected) and
mean JEV-specific ELISA end-point and PRNT50 titres (ranges in parentheses) were determined.
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and boosted once (JE-VAX group) or twice (ccJE groups)
at 5-week intervals. Comparison of PRNT50 titres against
JEV after two doses of vaccine showed that ccJE gave
approximately threefold higher responses than JE-VAX
(Table 6). When ccJE was formulated with Advax, the
neutralizing antibody responses were augmented four- and
sixfold relative to the unadjuvanted ccJE group after two
and three immunizations, respectively. A single booster
immunization was critically required to achieve high levels
of neutralizing antibody; however, the second boosters did
not result in significant further increases in titres.
Neutralizing antibody titres against MVEV and WNV were
also measured (Table 6). The data showed that formulation
of ccJE with Advax increased the cross-protective immun-
ity against both viruses. Accordingly, in this large-animal
model, the cross-protective value of inactivated JE vaccines
also strictly correlated with the magnitude of the
homologous responses.
DISCUSSION
Advax is a novel polysaccharide adjuvant based on
microparticles of delta inulin that is under development
for a range of vaccine applications (P.D. Cooper and N.
Petrovsky, patent application WO 2006/02410, PCT/
AU2005/001328: new polymorphic form of inulin and
uses thereof; in preparation). Here, we showed in mice, as
well as in a pre-clinical vaccination study in horses, that
formulation of inactivated JE vaccines with Advax greatly
enhances virus-specific immunity relative to unadjuvanted
forms of the same vaccines. Advax-mediated immune
Table 6. Neutralizing antibody titres in horses immunized with JE-VAX or ccJE without or in the presence of different Advax
formulations
NT, Not tested; GMT, geometric mean titre.
Vaccine* Horse Neutralizing antibody titre (PRNT50)
Post-prime Post-1st boost Post-2nd boost
JEV JEV MVEV WNV JEV MVEV WNV
JE-VAX #1 ,10 90 10 ,10 NT NT NT
#2 ,10 30 10 10 NT NT NT
GMT ,10 52 10 ,10
ccJE #3 30 100 80 10 100 40 10
#4 10 200 20 ,10 100 20 ,10
#5 ,10 200 40 ,10 200 10 ,10
#6 10 200 40 ,10 200 10 ,10
GMT 11 168 40 ,10 141 17 ,10
ccJE+Advax #7 10 800 40 30 1600 80 10
#8 30 1600 160 30 1600 320 90
#9 10 200 20 10 200 20 10
GMT 14 635 50 21 800 80 21
*Horses were immunized subcutaneously with 6 mg doses of JE-VAX, ccJE or Advax-adjuvanted ccJE. The vaccination schedule was as follows: week
0, first dose; week 5, second dose; week 10, third dose for ccJE±Advax adjuvant group only. Sera were tested for antibody prior to commencement
of immunizations and found to be negative (data not shown). Serum collection was on the day of immunization at weeks 5 and 10, and at week 17.
Fig. 2. Stimulation of JEV serocomplex cross-neutralizing anti-
bodies with Advax-adjuvanted JE-VAX vaccine. Groups of 8-week-
old C57Bl/6 mice (n56) were immunized with 0.5 mg JE-VAX
without or formulated with Advax adjuvant and boosted 3 weeks
later. A third group was vaccinated with 10
5 p.f.u. ChimeriVax-JE,
but did not receive a booster immunization. At 6 weeks after
completion of the vaccination schedules, sera were collected and
anti-JEV ELISA end-point and PRNT50 titres against MVEV were
determined for individual sera. Dotted lines indicate the detection
limits of the assays. Solid lines indicate the mean value.
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http://vir.sgmjournals.org 1413potentiation had functional value in terms of increasing
the magnitude of neutralizing antibody responses and
provided complete protection of mice from intranasal
challenge with JEV. The Advax adjuvant enhanced the
immunogenicity of both mouse brain- and cell culture-
grown JE vaccine antigens to a comparable degree: in both
cases, JEV-specific ELISA antibody titres were augmented by
up to 100-fold and neutralization titres by 10–50-fold when
approximately one-tenth of a human dose of vaccine was
used in a two-dose immunization schedule in the mouse
studies. Importantly, this vaccination regimen resulted in all
mice (five separate experiments, two inbred mouse strains)
responding with PRNT50 titres ¢20, which is indicative of
solid protective immunity against JEV infection. This
contrasted with a sizeable incidence of vaccine failure
(PRNT50 ,10) in recipients of the unadjuvanted vaccines.
In human immunizations, a two-dose vaccination schedule
with JE-VAX failed to generate detectable neutralizing
antibody in ~20% of vaccine recipients (Poland et al.,
1990) and three doses were required for adequate humoral
immunity in .90% of immunized individuals (reviewed by
Halstead & Tsai, 2004). Accordingly, the mouse model
resembles immunization in humans with JE-VAX with
respect to the relatively inefficient induction of neutralizing
antibody. Given the potent immune stimulation of inacti-
vated JE vaccines with Advax adjuvant in mice, and in view
of recent results from trials using hepatitis B and influenza
virus antigens, which showed that Advax is fully effective in
human subjects (unpublished results), we anticipate that
Advax will similarly augment immunity in human vaccina-
tion against JEV.
A remarkable property of Advax when formulated with
ccJE was the level of dose sparing of antigen that could be
achieved. Thus, a two-dose immunization schedule of mice
with a 100-fold lower amount of antigen (50 ng) than
recommended for use in humans elicited protective levels
of neutralizing antibody that were comparable to those
induced with prime–boost immunization with 10
5 p.f.u.
live ChimeriVax-JE vaccine. Whilst alum-adjuvanted IC51
(Jespect) vaccine was comparably immunogenic to Advax-
adjuvanted ccJE at a high antigen dose (0.5 mg antigen), it
was significantly less effective following a tenfold dose
reduction. This side-by-side comparison highlights the
greater immune-potentiating value of Advax relative to
alum in formulations with ccJE. It is an important clinical
consideration and may be indicative of a reduced risk of
vaccine failure with Advax- relative to alum-adjuvanted JE
vaccines. Furthermore, whereas alum adjuvant is recog-
nized to impart major Th2 bias to vaccine responses, as
demonstrated by predominant induction of IgG1 and IgE
antibody isotypes in mice, Advax adjuvant provided a
balanced enhancement of both Th1 and Th2 responses, as
demonstrated by induction of JEV-specific IgG2b as well as
IgG1 in C57Bl/6 mice.
Equine vaccinations with Advax-adjuvanted ccJE con-
firmed the efficient immune-potentiating property of
Advax in a large-animal model. Fourfold increases in
neutralizing antibody responses against JEV were achieved
in comparison with unadjuvanted ccJE, in a two-dose
vaccination schedule. A third dose of either adjuvanted or
unadjuvanted ccJE did not boost the humoral immune
responses further. These results have significant impli-
cations in terms of improved JE vaccine efficacy and
potential antigen dose sparing for veterinary and human
immunization.
A second key finding of this study was the demonstration
of protective levels of cross-neutralizing antibody against
related viruses belonging to the JEV serocomplex in mice
and horses vaccinated with ccJE vaccine only when
formulated with Advax adjuvant. This may be important
in terms of human health when vaccination against JEV is
considered for a population residing in endemic areas or
for travellers to regions where related flaviviruses such as
WNV or MVEV co-exist with JEV. We and others have
shown in animal models that, in these circumstances, the
induction of cross-neutralizing antibody is a desirable
property of a JE vaccine not only for the benefit of
protection against the other pathogens, but also to reduce
the potential risk of immune enhancement of infection
with a heterologous flavivirus (Broom et al., 2000; Lobigs et
al., 2003, 2009). In the absence of adjuvant, the inactivated
JE vaccines induced low and often undetectable levels of
neutralizing antibody against MVEV and WNV. A similar
observation has been made in humans immunized with JE-
VAX (Kanesa-Thasan et al., 2002) or live SA14-14-2 JE
vaccine (Tang et al., 2008). In contrast, we demonstrated
that the inclusion of Advax with JE-VAX or ccJE
consistently induced and boosted JEV serocomplex cross-
neutralizing immunity in mice and horses, suggesting that
protection against multiple related flaviviruses can be
achieved using a single Advax-adjuvanted inactivated JE
vaccine.
The mechanism by which Advax adjuvants stimulate
vaccine immunogenicity remains under investigation.
This and other investigations (Petrovsky, 2006; Silva
et al., 2004) have shown that the adjuvant does not give
rise to a polarization of the CD4
+ T-cell responses against
the vaccine antigen. Balanced cellular and humoral
immunity elicited with Advax-adjuvanted JE vaccines in
terms of the Th1/Th2 paradigm may be a factor, in
addition to the potent enhancement of the magnitude of
the antibody response, that contributes to stimulation of
cross-neutralizing immunity and thereby reduces the risk
of vaccine-induced enhanced susceptibility to heterologous
flaviviruses. Notably, a Th2 bias in the immune response
induced by vaccination has been associated with disease
enhancement (see, for example, Huisman et al., 2009;
Moghaddam et al., 2006; Polack, 2007; Yang et al., 2001). If
this were also the case in infections with JEV and related
flaviviruses, adjuvants that produce a strong Th2 bias, such
as alum salts (McKee et al., 2007), could compromise
vaccine safety and may be better replaced in human
vaccines by adjuvants such as Advax that provide a more
balanced immune enhancement.
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Animals. C57Bl/6 and BALB/c mice were bred under specific-
pathogen-free conditions and supplied by the Animal Breeding
Facility at the John Curtin School of Medical Research, Australian
National University (ANU), Canberra, Australia. Female mice were
used in all experiments. All animal experiments were approved by the
ANU or the University of Queensland animal ethics committees.
Viruses. Working stocks of JEV (strain Nakayama), MVEV (strain
MVE-1-51) and WNV (strain Kunjin MRM61C/60) were 10%
suckling mouse brain homogenates in Hanks’ balanced salt solution
containing 20 mM HEPES buffer (pH 8.0) and 0.2% BSA (HBSS-
BSA). Virus titres were determined by plaque formation on Vero cells,
as described previously (Licon Luna et al., 2002).
Vaccines and adjuvant. JE-VAX (Sanofi Pasteur Inc.) was prepared
prior to immunizations as recommended by the supplier. A human
dose of this vaccine contains ~6 mg purified, formalin-inactivated JEV
(Nakayama strain). Vero cell culture-grown inactivated ccJE vaccine
(Beijing-1 strain) (Toriniwa & Komiya, 2008) was obtained from the
Kitasato Institute, Japan. ChimeriVax-JE (Monath et al., 2003) was
propagated for one passage in Vero cells grown in M199 medium
(Invitrogen) supplemented with 5% fetal bovine serum and
antibiotics. The clarified infected culture supernatant had a titre of
1610
7 p.f.u. ml
21 in Vero cells and was frozen in single-use aliquots.
Immunization with each of the vaccines was by the subcutaneous
route. Advax D adjuvant, which is based on microparticulate delta
inulin, was obtained from Vaxine Pty Ltd, Adelaide, Australia. Advax
is supplied as a sterile, preservative-free, fine particulate suspension of
delta inulin particles in a phosphate buffer at neutral pH and has a
milky white appearance similar to alum. The adjuvant is prepared
from inulin [b-D-(2A1)polyfructofuranosyl a-D-glucose], a natural
plant-derived polysaccharide found in nature mainly as a storage
polysaccharide in the roots of the Compositae family of plants. Inulin
comprises a chain of fructose units originating from a single glucose
unit. It has a structure unusual in a polysaccharide in that the
polymer backbone does not pass through a sugar residue but
comprises a hydrophobic polyoxyethylene chain of -C-C-O- linkages.
Inulin’s relatively hydrophobic, polyoxyethylene-like backbone plus
its non-ionized nature allow inulin to be crystallized into various
isomorphic forms, of which delta inulin is the most temperature-
stable and adjuvant-active isoform. Advax adjuvant was combined
with antigen by simple admixture immediately prior to immuniza-
tion. Unlike aluminium salt adjuvant, Advax adjuvant does not
adsorb the antigen when mixed and hence the combined formulation
can be injected immediately after mixing. Vaccines (ccJE or JE-VAX)
were diluted in PBS to the required antigen concentration, as
indicated, with or without formulation with Advax (10 mg ml
21 final
concentration) or alum (aluminium phosphate, 20 mg ml
21 final
concentration) prior to injection of a volume of 0.1 ml of the
adjuvanted vaccines. Jespect was purchased from CSL Ltd, Australia; a
0.5 ml dose of the vaccine contains 6 mg inactivated JEV (SA14-14-2
strain). The vaccine was diluted in PBS containing 0.1% aluminium
hydroxide to obtain the required antigen doses, as indicated.
Horse immunization. Groups of standard bred, female horses, 4–8
years of age and seronegative for JEV, MVEV and WNV, were
immunized with JE vaccines by subcutaneous injections. Horses were
boosted once or twice at 5-week intervals, as indicated, and sera were
collected at 5 weeks after the first and second, and 7 weeks after the
third immunization.
Serological tests. For titration of JEV-reactive antibody in mouse
serum, ELISAs were performed with horseradish peroxidase-
conjugated goat anti-mouse Ig and the peroxidase substrate 2,29-
azino-di(3-ethyl-benzthiasoline sulfonate) as described previously
(Colombage et al., 1998). The JEV Nakayama strain was used for
ELISA antigen production. For determination of ELISA end-point
titres, absorbance cut-off values were established as the mean
absorbance of eight negative-control wells containing sera of naı ¨ve
mice plus 3 SD. Absorbance values of test sera were considered
positive if they were equal to or greater than the absorbance cut-off
and end-point titres calculated as log10 of the reciprocal of the last
dilution giving a positive absorbance value.
A PRNT50 was performed by incubating ~400 p.f.u. JEV (Nakayama
strain), MVEV (MVE-1-51 stain) or WNV (Kunjin MRM61C strain)
in 110 ml HBSS-BSA with serial twofold dilutions of antiserum in the
same buffer in a 96-well tray at 37 uC for 1 h. Complement was
inactivated by heating the sera at 56 uC for 0.5 h before use. Duplicate
0.1 ml aliquots were assayed for infective virus by plaque formation
on Vero cell monolayers grown in six-well tissue culture trays. The
percentage plaque reduction was calculated relative to virus controls
incubated with naı ¨ve serum from the same mouse strain. Controls
yielded 50–100 p.f.u. per well. PRNT50 titres are given as the
reciprocal of serum dilutions that resulted in a ¢50% reduction in
the number of plaques.
The isotypes of JEV-specific antibodies in serum samples were
determined using an ELISA-based Mouse Typer Subisotyping kit
(Bio-Rad) according to the supplier’s instructions. JEV-coated ELISA
trays were used and serum samples were diluted 100-fold in Blotto/
Tween 20 and assayed in duplicate. Three naı ¨ve control sera were
included in each test. To determine the relative isotype titres, the
mean absorbance values of test sera were divided by twice the
corresponding mean absorbance value of the control sera.
Statistics. Differences in survival ratios in mouse challenge
experiments were assessed using Fisher’s exact test, and a Wilcoxon
signed-rank test was used to assess differences in antibody titres for
significance. Samples with titres below the detection limit of the
serological assays were given titres of half that of the detection limit
for calculations.
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